Bavarian Nordic A/S (Bavarian Nordic A/S) ROCE %

: 36.43% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bavarian Nordic A/S's annualized ROCE % for the quarter that ended in Dec. 2023 was 36.43%.

Bavarian Nordic A/S ROCE % Historical Data

The historical data trend for Bavarian Nordic A/S's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-8.54

7.43

-3.25

-2.02

14.85

Bavarian Nordic A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															10.69	15.21	19.37	-11.67	36.43

Bavarian Nordic A/S ROCE % Calculation

Bavarian Nordic A/S's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	232.408	/	( ( (1764.406 - 325.697)	+	(2100.019 - 407.893) )	/ 2 )
	=	232.408	/	( (1438.709	+	1692.126)	/ 2 )
	=	232.408	/	1565.4175
	=	14.85 %

Bavarian Nordic A/S's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	582.18	/	( ( (1917.546 - 413.165)	+	(2100.019 - 407.893) )	/ 2 )
	=	582.18	/	( ( 1504.381	+	1692.126 )	/ 2 )
	=	582.18	/	1598.2535
	=	36.43 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Bavarian Nordic A/S (OTCPK:BVNRY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bavarian Nordic A/S ROCE % Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic A/S's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bavarian Nordic A/S (Bavarian Nordic A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OTCPK:BVNRY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BVNKF:USA BAVAc:UK 0DPB:UK BAVA:Denmark BV3:Germany

Address

Philip Heymans Alle 3, Hellerup, DNK, DK-2900

Website

https://www.bavarian-nordic.com

Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.